Introduction
============

The primary goal of treating patients with chronic inflammatory arthritis (CIA) is remission or low disease activity achieved by controlling the symptoms and inflammation ([@b48], [@b3], [@b16]). The term 'CIA' refers to rheumatoid arthritis (RA) and spondyloarthritis ([@b8]). Cut-off points have been developed to determine whether a patient is in clinical remission or a state of low disease activity. No single instrument can adequately describe the disease process for every patient. Disease activity is, therefore, evaluated by composite measures comprising patient- and practitioner-reported outcomes. One frequently used composite measure is the Disease Activity Score 28 (DAS28) ([@b12]). Previous research has led to the development of biological therapy for patients with an inadequate response to traditional disease-modifying anti-rheumatic drug (DMARD) therapies. Biological DMARD therapies have transformed the rheumatology landscape and are rapidly becoming more common as new therapies are developed for a greater number of indications ([@b14]). Previous research has shown that biological therapy leads to improvements in disease activity, health status, physical function and quality of life ([@b29]). Disease activity and inflammation in patients with CIA have declined over the past decade since the introduction of biological therapy ([@b47]).

In Sweden, patients with CIA undergoing biological therapy are usually monitored by a rheumatologist every 6 months to evaluate the effect of the medication and the disease activity measured by the DAS28. Data are stored in the Swedish Rheumatology Quality (SRQ) register ([@b55], [@b34]). Biological therapies are either intravenous infusions administered by a nurse or self-administered subcutaneous injections. Patients perceive the regular contact with a nurse in conjunction with the infusions as secure, invigorating and leading to involvement ([@b22]). When treated with subcutaneous injections, a nurse teaches the patients how to administer the injection, but some patients report missing regular contact with a nurse ([@b23]). The nurse\'s role has developed into that of an expert with in-depth nursing knowledge and competence of how to provide evidence-based care and support patients to become co-actors in the care ([@b1], [@b35], [@b33]). Collaboration between patient and nurse is a prerequisite for participation and making patients co-actors ([@b43]). In qualitative studies, patients have described how nurses provide added value to patient care by their holistic approach. The nurse creates familiarity and patients dare to open up to a nurse who listens attentively to their problems ([@b2], [@b41], [@b24]).

Background
==========

Nurse-led clinics are established as a complement to physician-led clinics in the management of, for example, cardiovascular and pulmonary diseases as well as diabetes and cancer ([@b50], [@b21], [@b6], [@b4]). Patients experienced greater well-being and satisfaction with the care in nurse-led clinics as well as improved quality of care ([@b58], [@b26], [@b5], [@b4], [@b44]). To enhance the quality of care by means of a more holistic approach, nurse-led rheumatology clinics have been proposed for patients with low disease activity or in remission who are undergoing biological therapy ([@b35], [@b33]). Nurse-led clinics will enable the rheumatologist to prioritize and allocate more time to patients with early RA or high disease activity who require more frequent monitoring or change in medication, leading to the desired treatment outcome ([@b17], [@b45]).

A systematic review ([@b31]) only identified four small UK and Dutch randomized controlled trials (RCTs) focusing on nurse-led rheumatology clinics that employ traditional therapies among patients with RA. Patients who visit a nurse-led rheumatology clinic every or every second month report a high level of satisfaction. They also have greater knowledge of the disease and treatment in addition to positive results in terms of disease activity, functioning and health as well as less pain. A more extensive RCT (*n *= 287) from Denmark demonstrated that nurse-led consultations increased self-efficacy beliefs in patients with established RA who received traditional therapies. Disease activity, physical disability, pain and fatigue did not differ over 1 year between nurse-led follow-up, traditional monitoring by a rheumatologist and no planned consultation ([@b38]). When reviewing the literature, no trial was found within rheumatological care that focused on comparing treatment outcomes from a nurse-led rheumatology clinic, where every second visit to the rheumatologist was replaced by one to a rheumatology nurse in patients undergoing biological therapy who had low disease activity or were in remission. Accordingly, the hypothesis of this RCT was that the treatment outcomes measured by the DAS28 in patients with low disease activity or in remission, undergoing biological therapy at a nurse-led clinic, would not be inferior to those of a rheumatologist-led clinic at the 12-month follow-up.

The study
=========

Aim
---

The aim of this trial was to compare and evaluate treatment outcomes of a nurse-led rheumatology clinic and a rheumatologist-led clinic in patients with low disease activity or in remission undergoing biological therapy.

Methods
=======

Design
------

An RCT was designed and the intention was to replace one of the two annual rheumatologist monitoring visits by a nurse-led rheumatology monitoring visit in patients undergoing biological therapy. Patients with CIA undergoing biological therapy with low disease activity or in remission completed a pre-test before inclusion, a test at the 6-month and the 12-month follow-up visit. The trial was conducted at a rheumatology clinic in Sweden. The hospital had 30 inpatient beds for patients with rheumatic diseases and 5500 outpatient visits annually for 3500 patients, of whom 600 were undergoing biological therapy.

Participants
------------

Inclusion criteria were patients with CIA, undergoing biological therapy and DAS28 ≤3·2. In this trial, patients with RA, undifferentiated arthritis, undifferentiated spondyloarthritis (USpA) and psoriatic arthritis (PsA) were included if they had peripheral arthritis. Patients with recurrent infections or adverse events due to the biological therapy were excluded. A total of 270 patients were assessed by a rheumatologist, of whom 125 met the inclusion criteria and were invited to participate. The participants who agreed to take part in the trial (*n *= 107) were randomly assigned to either the nurse-led rheumatology clinic (intervention group; *n *= 53) or the rheumatologist-led clinic (control group; *n *= 54). Randomization took the form of sealed envelopes containing assignment to one of the two groups. The envelopes were mixed and when a patient met the inclusion criteria, an envelope was randomly picked. At inclusion, 18 patients decided not to participate*,* nine men and nine women ([Figure 1](#fig01){ref-type="fig"}), mean age 46·4 years ([sd]{.smallcaps} 17·1, 25--72 years) and a mean disease duration of 12·8 years ([sd]{.smallcaps} 8·9, 1--35 years). Those who agreed to participate were significantly older (*P *\< 0·01), but there were no other significant differences in demographic and clinical characteristics between the participants and non-participants.

![Flow chart of the participants in the study.](jan0070-0164-f1){#fig01}

A pre-trial power analysis was based on the primary outcome DAS28 score. A mean difference of 0·6 was considered a moderate improvement, while a difference of 1·2 was deemed clinically significant or good ([@b40]). Based on a change of 0·6 in the DAS28 score and a [sd]{.smallcaps} of 1·0 ([@b39]), the power analysis demonstrated that 95 patients would be a sufficient number to detect a clinically moderate difference between groups at a 5% significance level with at least 90% power. It was decided to include 107 patients to allow for the predicted 10% dropout. The primary outcome measure was change in the DAS28 over a 12-month period.

Intervention
------------

### Rheumatologist-led clinic

The usual care for patients with CIA undergoing biological therapy in Sweden is monitoring by a rheumatologist every 6 months for 30 minutes to evaluate the effect of the medication and the disease activity measured by the DAS28 ([@b55]). The rheumatologist assessed disease activity by examining tender and swollen joints based on a 28-joint count in addition to evaluating the results of laboratory tests. The patients were able to contact the rheumatology clinic between the scheduled follow-up visits.

### Nurse-led rheumatology clinic

A nurse-led rheumatology clinic based on person-centred care focusing on patient needs was designed. The purpose of person-centred care is to give patients the opportunity to talk about themselves as a person and to allow their illness narrative to constitute a starting point for building collaboration, which encourages and empowers them to play an active role in their biological therapy and find solutions to their problems ([@b10]). Patients were monitored for 30 minutes by a rheumatology nurse after 6 months*,* followed by 30 minutes monitoring by a rheumatologist after 12 months. The patients had the opportunity to contact the nurse during the 12-month trial period. The nurse assessed the patients\' disease activity by examining tender and swollen joints based on the 28-joint count in addition to evaluating the results of laboratory tests in the same way as a rheumatologist. Drug treatment was discussed in terms of administration, adherence, side effects and laboratory tests as well as patients\' global health. Patients\' narratives constituted the starting point of a dialogue to meet individual needs and included lifestyle and psychosocial aspects. Such narratives created a common understanding of the illness experience, which, together with the symptoms of disease, provided the nurse with a good foundation for discussing and planning care and treatment with the patients ([@b10]). Five Registered Nurses with 22--39 years\' professional experience and 9--20 years\' experience of managing rheumatic diseases in both inpatient and outpatient rheumatology care participated in the trial. They had undergone special training from a rheumatologist and RA instructors to assess swollen and tender joints based on the 28-joint count to make an evidence-based assessment of disease activity. RA instructors are specially trained patients who instruct healthcare staff how to examine the joints of the hands, wrists, feet and ankles, and provide information about living with the disease. If necessary, the nurse could contact the rheumatologist for advice or to obtain a prescription.

Data collection
---------------

Data collection took place between October 2009--August 2011. Data were collected at baseline, 6 and 12 months and entered into the SRQ register. The monitoring by the rheumatology nurse (intervention group) and the rheumatologist (control group) included an assessment of the number of swollen and tender joints based on the DAS28. The participants indicated their perceived global health the previous week (0--100, best to worst) on a 100-mm Visual Analogue Scale (VAS). The Health Assessment Questionnaire (HAQ), VAS for pain and the Numerical Rating Scale (NRS) for assessment of satisfaction with and confidence in obtaining rheumatology care were used. An assessment of disease activity, medication record, employment status and any adverse events were also documented. The primary outcome was disease activity measured by the DAS28. All patients were monitored by the rheumatologist at baseline and after 12 months.

### Instruments

The DAS28 is a validated index of RA disease activity ([@b37]) and a composite measurement comprising patient-reported (number of tender joints based on the 28-joint count and global assessment, VAS for global health) and practitioner-reported \[number of swollen joints based on the 28-joint count and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\] scores. The outcome of the DAS28 is a number on a scale from 0 to 10, where the values \>5·1, \<3·2 and \<2·6 indicate high disease activity, low disease activity and remission respectively ([@b12]). The DAS28 is also used to measure disease activity in other inflammatory joint diseases, such as peripheral PsA and USpA ([@b13], [@b42], [@b15]), and constitutes a variable for evaluating disease activity in patients treated by means of biological therapy ([@b54]). In this trial, the abbreviation DAS28 was used when the calculation included the ESR, while DAS28-CRP was employed when the calculation included CRP, and the correlation between them was found to be good ([@b56]).

The HAQ is a self-administered, disease-specific questionnaire for assessing activity limitation in patients with arthritis. It measures the ability to perform 20 items and assesses the degree of difficulty involved in performing activities of daily living during the previous week. The activities are grouped into eight categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The total score ranges from 0--3 and a higher score indicates a greater degree of disability ([@b9]).

The VAS was used to assess pain during the previous week (VAS 0--100 mm). The anchor points of the scale are 0 (no pain) and 100 (worst possible pain) ([@b20]).

The level of satisfaction with and confidence in the rheumatology care was assessed by the NRS scored from 0 to 10. The questions were, 'How satisfied are you with the rheumatology care?' The anchor points of the scale are 0 (not at all satisfied) and 10 (completely satisfied). 'How confident are you of obtaining help from your rheumatology clinic when you have joint problems?' The anchor points of the scale are 0 (no confidence and 10 (complete confidence) ([@b28], [@b11]).

Validity and reliability
------------------------

Validated instruments with good psychometric properties were used to enhance the validity and reliability of the data. The instruments in the SRQ register intended to provide a standardized evaluation of the clinical and research aspects involved in monitoring the biological therapy ([@b55]). The DAS28, HAQ and VAS pain are well-validated ([@b9], [@b20], [@b37]) and have been used in routine disease assessments for measuring the response level of biological therapy in many clinical settings (e.g. Europe) ([@b14]).

Ethical considerations
----------------------

The regional Ethics Committee at Lund University, Sweden, approved the trial (No. 2009/245). The research conforms to the ethical principles for medical research on human beings set out in the declaration of Helsinki ([@b57]) and the national guidelines on ethical principles ([@b51]). According to the [@b32], this trial fulfils the four requirements on research: information, consent, confidentially and safety of the participant ([@b32]). Written informed consent was obtained from patients at their first visit before inclusion in the trial. They were advised about their right to withdraw at any time. This trial was registered at <http://clinicaltrials.gov> under the identification code NCT01071447.

Data analysis
-------------

Statistical analyses were performed using SPSS version 19.0 for Windows. Differences in disease activity, activity limitation, pain, satisfaction with and confidence in obtaining rheumatology care between groups were analysed by means of an independent sample *t*-test and within the groups by a paired *t*-test. Due to the properties of the scales, VAS Pain, VAS Global health, HAQ, NRS Satisfaction and NRS Confidence were analysed by both parametric (*t*-test) and non-parametric (Mann--Whitney [U]{.ul} test and Wilcoxon signed ranks test) methods. Values of *P *\< 0·05 were considered statistically significant.

Results
=======

Participant characteristics
---------------------------

In all, 97 participants completed the trial. The baseline characteristics of the intervention and control groups as well as the dropouts are presented in [Table 1](#tbl1){ref-type="table"} in terms of sociodemographic, clinical and outcome variables ([Table 1](#tbl1){ref-type="table"}). There were similar numbers of men and women in the intervention group (45% vs. 55%) and the control group (44% vs. 56%), but a greater difference within the dropout group (30% vs. 70%). The mean age was 55·0 ([sd]{.smallcaps} 12·3, range 34--81 years) in the intervention group and 55·8 years ([sd]{.smallcaps} 13·2, range 21--77 years) in the control group. The dropouts were slightly younger with a mean age of 51·1 years (16·0, range 24--70 years). After 6 months, 50 patients (94%) in the intervention group were monitored by a rheumatology nurse at the follow-up visit, while 53 patients (98%) in the control group were monitored by the rheumatologist. In total, 47 patients (89%) in the intervention group and 50 patients (93%) in the control group completed the 12-month trial. The reasons for dropping out were medical (changed therapy or other diseases), moving to another area and death. The flow chart depicted in [Figure 1](#fig01){ref-type="fig"} visualizes the flow during the trial.

###### 

Baseline sociodemographic and clinical characteristics of the intervention and control groups including dropouts

  Characteristics                              Intervention group   Control group   Dropouts
  -------------------------------------------- -------------------- --------------- -------------
  Sex                                                                               
   Male                                        21 (45%)             22 (44%)        3 (30%)
   Female                                      26 (55%)             28 (56%)        7 (70%)
  Age (years)                                                                       
   Mean age ([sd]{.smallcaps})                 55·0 (12·3)          55·8 (13·2)     51·1 (16·0)
   Range                                       34--81               21--77          24--70
  Civil status                                                                      
   Living alone                                12 (26%)             11 (22%)        4 (40%)
   Co-habiting                                 35 (74%)             39 (78%)        6 (60%)
  Education                                                                         
   Primary school                              15 (32%)             14 (28%)        5 (50%)
   Secondary school                            15 (32%)             15 (30%)        3 (30%)
   Third level education                       17 (36%)             21 (42%)        2 (20%)
  Rheumatic disease                                                                 
   Rheumatoid arthritis (RA)                   25 (53%)             35 (70%)        8 (80%)
   Undifferentiated arthritis (UA)             1 (2%)               3 (6%)          0
   Undifferentiated spondyloarthritis (USpA)   10 (21%)             6 (12%)         1 (10%)
   Peripheral psoriatic arthritis (PsA)        11 (23%)             6 (12%)         1 (10%)
  Disease duration (years)                                                          
   Mean disease duration ([sd]{.smallcaps})    17·3 (10·9)          16·2 (12·1)     14·0 (6·9)
   Range                                       1--44                1--52           1--21
  Disease activity DAS28                                                            
   Mean ([sd]{.smallcaps})                     1·97 (0·67)          2·14 (0·71)     2·39 (0·60)
   Range                                       0·61--3·20           0·53--3·06      1·47--3·13
  Disease activity DAS28-CRP                                                        
   Mean ([sd]{.smallcaps})                     2·43 (0·58)          2·53 (0·64)     2·65 (0·49)
   Range                                       1·74--4·10           1·71--4·12      2·02--3·23
  Health Assessment Questionnaire (HAQ)                                             
   Mean ([sd]{.smallcaps})                     0·45 (0·42)          0·63 (0·55)     0·43 (0·59)
   Range                                       0--2·13              0--2·50         0--1·88
  VAS Pain (mm)                                                                     
   Mean ([sd]{.smallcaps})                     17·8 (11·5)          24·2 (22·2)     17·2 (16·9)
   Range                                       0--48                0--79           0--59
  Satisfaction (0--10)                                                              
   Mean ([sd]{.smallcaps})                     9·6 (0·80)           9·4 (1·28)      9·8 (0·42)
   Range                                       7--10                3--10           9--10
  Confidence (0--10)                                                                
   Mean ([sd]{.smallcaps})                     9·7 (0·66)           9·3 (1·45)      9·8 (0·63)
   Range                                       7--10                2--10           8--10

Primary outcome
---------------

Disease activity was assessed by the DAS28 and DAS28-CRP total score. There were no statistically significant differences in changes in the DAS28 (*P *= 0·66) or DAS28-CRP (*P *= 0·70) between the intervention and control group. The DAS28 is calculated using the results of the number of swollen and tender joints based on the 28-joint count, the VAS for global health and the ESR or CRP. There was a statistically significant, but not clinically relevant, difference in mean change of the individual CRP measurement (*P *= 0·03) between the intervention and the control group. In each of the other individual measurements, there were no significant mean changes between the groups.

Within both groups, there were small, but not clinically relevant, deteriorations in the DAS28 score (intervention group 0·14; *P *= 0·19; control group 0·20; *P *= 0·048) between baseline and the 12-month follow-up. Within the control group, there were small, but not clinically relevant, deteriorations in CRP (1·20; *P *= 0·01) between baseline and the 12-month follow-up. In each of the other individual measurements (number of swollen and tender joints based on the 28-joint count, VAS for global health and ESR), there were no significant mean changes within the groups ([Table 2](#tbl2){ref-type="table"}).

###### 

Comparison of mean change after 12 months between and within the intervention group (Nurse-led rheumatology clinic) (*n *= 47) and control group (Rheumatologist-led clinic) (*n *= 50)

                                                            Intervention group -- Control group   Intervention group   Control group                                                      
  --------------------------------------------------------- ------------------------------------- -------------------- --------------- ------- ------------- ------ ------- ------------- ------
  DAS28                                                     −0·06                                 −0·34, 0·22          0·66            0·14    −0·07, 0·34   0·19   0·20    0·00, 0·39    0·05
  DAS28-CRP                                                 0·05                                  −0·28, 0·19          0·70            0·14    −0·03, 0·31   0·10   0·10    −0·07, 0·26   0·24
  ESR (mm/h)                                                −1·05                                 −3·97, 1·86          0·47            1·09    −0·40, 2·57   0·15   2·14    −0·36, 4·64   0·09
  CRP (mg/L)                                                −1·07                                 −2·02, −0·12         0·03            0·13    −0·10, 0·35   0·26   1·20    0·29, 2·10    0·01
  Swollen joints (28)                                       0·13                                  −2·18, 0·61          0·60            0·13    −0·27, 0·53   0·52   0·00    −0·29, 0·29   1·00
  Tender joints (28)                                        0·33                                  −0·47, 1·13          0·42            0·47    −0·05, 0·99   0·08   0·14    −0·47, 0·75   0·65
  VAS Global health (mm)[\*](#tf2-2){ref-type="table-fn"}   4·29                                  −2·58, 11·16         0·22            2·49    −2·59, 7·56   0·33   −1·80   −6·57, 2·97   0·45
  VAS Pain (mm)[\*](#tf2-2){ref-type="table-fn"}            −0·24                                 −7·89, 7·40          0·95            0·98    −4·74, 6·69   0·73   1·22    −4·02, 6·47   0·64
  HAQ[\*](#tf2-2){ref-type="table-fn"}                      0·02                                  −0·10, 0·13          0·79            0·04    −0·04, 0·12   0·34   0·02    −0·05, 0·10   0·51
  NRS Satisfaction[\*](#tf2-2){ref-type="table-fn"}         0·25                                  −0·37, 0·88          0·43            −0·19   −0·57, 0·18   0·31   −0·44   −0·94, 0·06   0·09
  NRS Confidence[\*](#tf2-2){ref-type="table-fn"}           0·20                                  −0·29, 0·69          0·42            0·00    −0·22, 0·22   1·00   −0·20   −0·63, 0·23   0·36

Independent sample *t*-test for comparison between and Paired *t*-test for comparison within the groups.

Also analysed by Mann--Whitney *U* test and Wilcoxon signed ranks test with non-significant (*P* \> 0·05) results.

DAS, Diseases Activity Score (scale 0--10); ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Swollen and Tender joint (28 count); VAS, Visual Analogue Scales, VAS Global health (scale 0--100 best to worse), VAS Pain (scale 0--100 best to worse); HAQ, Health Assessment Questionnaire (0--3 best to worse); NRS, Numerical Rating Scale, NRS Satisfaction and NRS Confidence (0--10 worse to best).

Secondary outcomes
------------------

Physical difficulties in performing activities of daily living were measured by the HAQ. There were no statistically significant (*P *= 0·79) differences in mean change after 12 months in the HAQ or in pain assessed by VAS (*P *= 0·95) between the intervention and the control group. Nor were there any statistically significant differences between the groups after 12 months in terms of satisfaction with (*P *= 0·43) and confidence (*P *= 0·42) in obtaining rheumatology care. Within the intervention group and the control group, there were no statistically significant mean changes in HAQ, VAS pain, satisfaction with or confidence in obtaining rheumatology care ([Table 2](#tbl2){ref-type="table"}).

Discussion
==========

The hypothesis of this RCT was that the treatment outcomes measured by the DAS28 at a nurse-led clinic would not be inferior to those from a rheumatologist-led clinic at the 12-month follow-up. This hypothesis was supported by the trial. There were no differences in the treatment outcomes measured by DAS28 at a nurse-led clinic compared with a rheumatologist-led clinic at the 12-month follow-up. Monitoring of the patients\' biological therapy in the nurse-led rheumatology clinic resulted in no deterioration compared with monitoring in the rheumatologist-led clinic. When comparing disease activity between the two groups, the primary outcome revealed no significant difference. The main finding of this trial was that follow-up care by a rheumatology nurse for patients with stable CIA can be delivered with comparable safety and effectiveness to that provided by a rheumatologist. Similar results were found in other RCTs of nurse-led clinics and in different patient groups where the visit to a physician was replaced by one to a nurse ([@b30], [@b44]). A nurse-led rheumatology clinic based on person-centred care is one way to implement the European League Against Rheumatism (EULAR) recommendations pertaining to the role of nurses in the management of CIA, which state that, 'Nurses should participate in comprehensive disease management to control disease activity, to reduce symptoms and to improve patient-preferred outcomes' ([@b8], p. 15). A nurse-led clinic can meet the EULAR recommendations, as it provides patients with improved knowledge of CIA and its management as well as enhancing communication, continuity and satisfaction with care ([@b8]). Other nurse-led clinics have reported similar clinical outcomes with high levels of satisfaction with consultations undertaken by a nurse compared to a physician ([@b49], [@b25]). The result of this trial did not reveal any differences in satisfaction with or confidence in obtaining care between the two groups. This may be due to the fact that patients in the intervention group were monitored just once by the nurse during the 12 months. Nevertheless, the hypothesis was supported by the trial and the nurse-led clinic intervention based on person-centred care with focus on the whole person proved safe and purposeful. The satisfactory results of the trial could be due to the nurse assessing the disease activity from a person-centred perspective and basing the care on patients\' view of their life situation. Medical assessment is important and should form the basis of care, but the patients\' own experiences of their condition must also be taken into consideration. The nurse\'s role is to provide care based on the patient\'s needs and to support her/him on the healthcare journey ([@b33]).

This trial has demonstrated that there is no clinically relevant difference in outcomes between a nurse-led rheumatology clinic and a rheumatologist-led clinic in patients with low disease activity or in remission, undergoing biological therapy. Previous research has revealed that care provided by a nurse-led clinic has a similar long-term clinical outcome to inpatient and day patient team care in patients with RA and is thus an effective innovation ([@b53]). Data indicate that a holistic approach to patient care is an important element of good nursing in nurse-led clinics. Nurses acknowledge each patient as a unique person and try to develop a holistic understanding of the patients\' life context ([@b46]). Person-centred care includes a holistic approach and as an RCT does not capture the qualitative aspects, this RCT was complemented by a qualitative study. [@b24] interviewed patients about their experiences of the encounter with the nurse and the patients reported that such encounters led to a sense of security, familiarity and participation. A nurse-led rheumatology clinic for biological therapy contributed added value for patients within rheumatology care, which became more complete by replacing every second visit to a rheumatologist with one to a nurse. A nurse and a rheumatologist complement each other, as they encounter the patients from different perspectives ([@b24]). This is consistent with experiences of patients from nurse-led clinics in diabetes care ([@b7]).

Today*,* the role of the nurse involves comprehensive duties, but ultimately enhanced care is achieved by a more holistic approach ([@b35]) and person-centred care that supports patients in making an informed decision to improve their well-being. In essence, the expertise of the nurse specialist is multifaceted, involving a number of important components such as regular assessment of disease activity, support, information sharing, coordination and continuity of care ([@b33]).

Limitations
===========

Due to the growing demand for evidence-based practice, RCTs are considered the best method for testing the effect of nursing interventions, as they yield strong evidence. Through randomization and the use of a comparison group, i.e. standard care, the trial was as close as possible to clinical practice. RCTs are sometimes criticized for their artificiality ([@b36]), but the present intervention can be directly integrated into the clinical routine. To strengthen internal validity, it is important to ensure that the intervention nurses cannot influence aspects of the process such as recruitment, randomization or data analysis ([@b27]). In this trial, the nurses did not participate in any aspect of the research process other than the intervention. The researchers were not involved in the intervention or assessment of the patients. Furthermore, data were registered in the SRQ using validated instruments. Reliability refers to the extent to which results are consistent over time and whether the result of a trial can be reproduced with a similar methodology ([@b36]). The structure of the nurse-led clinic was designed for the trial, and both the nurse and the rheumatologist followed national and international management and treatment guidelines ([@b55]); thus, this trial can be reproduced with a similar methodology. A limitation is the short time perspective (12 months), as a 2-year follow-up would better identify the long-term effects. A threat to reliability is loss of data due to dropout ([@b36]). In this trial, 107 patients were enrolled from 125 potential participants (86%). The retention rate was high with 90% of the patients completing the 12-month follow-up. The dropout rate of 11% in the intervention group and 7% in the control group is acceptable and understandable.

Research indicates that a DAS28 measurement by a nurse is as effective as standard care provided by a rheumatologist ([@b19]). In this trial, the rheumatology nurses had between 9--20 years\' experience of managing rheumatology diseases in both inpatient and outpatient settings and had received education from a rheumatologist and RA instructors. Although nurses\' examination of patients\' joints is fairly new in Sweden, this is not the case in other countries where nurses have assessed the joints of patients for decades ([@b18], [@b52]). External validity concerns the extent to which evidence from RCT settings can be generalized to real-world clinical practice ([@b36]). Previous research on traditional therapies indicates that consultation with an expert rheumatology nurse in a drug monitoring clinic may add value in terms of improving patients\' perceived ability to cope with arthritis ([@b41]). Implementation of nursing consultations as part of follow-up care in patients with stable RA is recommended ([@b38]). This trial comprised patients with CIA and low disease activity or in remission, thus a broader patient population than in previous research, which in most cases only included patients with RA.

What is already known about this topicRheumatology nurses are able to assess the patients\' disease activity by examining tender and swollen joints when monitoring traditional therapies.Regular contact with a nurse every 1--3 months at a nurse-led rheumatology clinic adds value to care for patients with rheumatoid arthritis treated by means of traditional therapies.What this paper addsPatients with stable chronic inflammatory arthritis undergoing biological therapy could be monitored by a nurse-led rheumatology clinic without any difference in outcome as measured by the Disease Activity Score 28.Replacing one of the two annual rheumatologist visits by a nurse-led visit is safe and effective when monitoring biological therapy.This randomized controlled trial demonstrated that a nurse-led rheumatology clinic, based on person-centred care, provides favourable follow-up care in patients with stable chronic inflammatory arthritis undergoing biological therapy.Implications for practiceThe follow-up care of patients undergoing biological therapy could be developed by a nurse-led rheumatology clinic based on person-centred care as a complement to a rheumatologist-led clinic.A nurse-led rheumatology clinic based on person-centred care is one way of implementing the European League Against Rheumatism recommendations regarding the nurse\'s role in the management of chronic inflammatory arthritis.This study indicates that a nurse-led rheumatology clinic should be made available to a broader patient population and not only to patients with rheumatoid arthritis in rheumatology units.

Conclusions
===========

The nurse-led rheumatology clinic intervention based on person-centred care focusing on the whole person proved safe and purposeful. In monitoring of biological therapy treatment, outcomes of patients at a nurse-led rheumatology clinic were not inferior to those from a rheumatologist-led clinic at the 12-month follow-up. Patients with CIA undergoing biological therapy, with low disease activity or in remission, could be monitored by a nurse-led rheumatology clinic without any difference in outcome as measured by DAS28.

The clinical importance of this trial is the finding that biological therapy follow-up care can be effectively performed by a nurse-led clinic based on person-centred care. Thus, replacing every second visit to a rheumatologist by one to a rheumatology nurse facilitates the implementation of such clinics in everyday practice. If rheumatology nurses assume more comprehensive roles after specialized training, this trial would be applicable to the monitoring of therapies other than biological therapy and thus to a broader population. Further research is needed to evaluate the long-term effect and cost-effectiveness of a nurse-led rheumatology clinic for monitoring various therapies for patients with CIA.
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